Sageworth Trust Co Purchases New Shares in Amgen Inc. $AMGN

Sageworth Trust Co acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,110 shares of the medical research company’s stock, valued at approximately $742,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. grew its position in shares of Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares during the period. Curtis Advisory Group LLC bought a new stake in shares of Amgen during the fourth quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. lifted its holdings in Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after buying an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen in the fourth quarter valued at approximately $22,441,000. Finally, Robinhood Asset Management LLC bought a new position in Amgen in the fourth quarter valued at approximately $17,526,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Trading Down 0.0%

AMGN opened at $367.99 on Thursday. The firm’s fifty day moving average is $343.82 and its two-hundred day moving average is $348.97. The firm has a market cap of $198.61 billion, a PE ratio of 25.61, a price-to-earnings-growth ratio of 3.63 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the business earned $4.90 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.35 EPS for the current year.

Analysts Set New Price Targets

AMGN has been the subject of several recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 target price on shares of Amgen in a research report on Monday. Canaccord Genuity Group assumed coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $400.00 price objective on shares of Amgen in a research note on Wednesday, July 1st. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $355.73.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Truist raised its price target on Amgen to $340 while keeping a hold rating, and Cantor Fitzgerald reaffirmed a neutral view, signaling that analysts still see value in the name even after the recent run-up. Benzinga analyst update
• Positive Sentiment: Biotech sentiment got a lift after Jim Cramer called the group “the hottest in the market,” citing a potentially stronger M&A environment that could benefit large-cap players like Amgen. Cramer biotech commentary
• Neutral Sentiment: Amgen’s dividend drew fresh attention, with an article arguing the payout still appears supported, but near-term headwinds could limit upside until operational concerns fade. Dividend safety article
• Negative Sentiment: Amgen initiated voluntary nationwide recalls of certain Corlanor and Sensipar lots due to foreign substances and CGMP deviations, raising quality-control and compliance concerns for investors. Recall coverage
• Negative Sentiment: Repeated recall headlines are putting Amgen’s manufacturing standards and risk profile back in focus, which could pressure the stock despite earlier momentum. Valuation and recall story
• Negative Sentiment: While Amgen won a preliminary injunction blocking Colorado’s proposed 70% price cap on Enbrel, that legal fight underscores ongoing pricing risk for one of its key drugs. Enbrel pricing article

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.